Stocks › DNTH
Dianthus Therapeutics, Inc. /De/ (DNTH) stock analysis
SKIP 1% confidence · analysed Nov 3, 2026
On Nov 3, 2026, our model rated Dianthus Therapeutics, Inc. /De/ (DNTH) SKIP with 1% confidence at a price of $82.70. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 71, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is 1.6x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $117.88 and the swing low is $32.42; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The company reports a profit margin of 0.0% and revenue growth of +294.3%.
In its latest quarter it earned $-0.90 per share, which beat the $-0.91 analysts expected, with revenue +294.3% year over year.
Wall Street's average rating is 1.1 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $139.06.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.01 (SKIP). Technicals: RSI 70.92, MACD bullish, price below SMA50. Fundamentals: margin 0.0%, revenue growth 294.3%. Financial results: YoY revenue +294.3%, last EPS surprise +1.1%, next earnings 2026-11-05. Smart Money Concepts: ranging / no clear structure, price retesting a bearish order block. FinGPT news read: positive. Reference price $82.7; no trade levels (SKIP).
Past ratings for DNTH
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 3, 2026 | SKIP | 1% | $82.70 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on DNTH
- Nov 2, 2026: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Nov 2, 2026: Dianthus Therapeutics to Participate in Five Investor Conferences During November (GlobeNewswire)
Frequently asked questions
Is DNTH a buy right now?
As of Nov 3, 2026, our automated model rates Dianthus Therapeutics, Inc. /De/ (DNTH) SKIP with 1% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Dianthus Therapeutics, Inc. /De/ report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.